As healthcare systems evolve toward value-based and patient-centric care, the focus is no longer limited to delivering treatments but ensuring better health outcomes across the entire care continuum. This shift is driving the need for stronger collaboration between pharmaceutical companies, healthcare providers, and care delivery platforms to bridge gaps in diagnosis, treatment, monitoring, and recovery. In an exclusive conversation, Suhasini Deshmukh, Co founder and Director of MedRabbits Healthcare, shares with Dr. Asawari Savant from Elets News Network (ENN), about the integrated healthcare platforms that are emerging as critical enablers of continuous patient engagement and outcome-driven healthcare. Edited excerpts 

How can integrated healthcare platforms help pharma companies move from episodic engagement to continuous involvement across the patient journey?

The integrated healthcare platform offers an ideal opportunity for the bridging of the age-old divide in the areas of diagnosis, treatment, and care. In the past, there have been efforts to get pharmaceutical companies to be involved in providing medications, but the relationship would only last until after the patient had been prescribed the medication. With an integrated healthcare platform, however, all four areas of consultation, diagnostic services, home healthcare, and hospitalization become intertwined into one system.

This creates an interwoven process through which patients can be taken care of in a holistic way. For the pharmaceutical company, this means that its role changes from being transactional to that of being part of the process and contributing to ensuring that treatment takes place.

How critical is care continuity, from diagnosis to recovery, in ensuring that treatments translate into measurable, real-world outcomes?

Care continuity is absolutely critical in ensuring that clinical efficacy translates into real-world effectiveness. While a diagnosis and prescription mark the beginning of treatment, the true value of therapy is realized only when patients are consistently supported through their recovery journey.

Breakdowns in continuity, such as missed follow-ups, poor adherence, or lack of monitoring, often lead to suboptimal outcomes, even with the most effective treatments. Continuous engagement ensures that patients remain compliant, complications are identified early, and interventions are timely. In an outcome-driven healthcare model, continuity is not just beneficial, it is essential to achieving measurable, sustained health improvements.

As integrated care models gain traction, how are they reshaping the way pharma companies engage with both patients and providers?

Integrated care models are fundamentally reshaping pharma engagement by shifting the focus from product-centric interactions to patient- and outcome-centric collaboration. Pharma companies are increasingly becoming part of a broader care ecosystem, working more closely with providers and engaging patients beyond traditional touchpoints.

This evolution is driving more personalized, data-informed engagement strategies. Pharma is now better positioned to contribute to patient support programs, co-create care pathways with providers, and generate real-world evidence that reflects how treatments perform outside controlled clinical settings. The emphasis is moving toward collaboration, shared accountability, and measurable outcomes.

What role can care delivery platforms like MedRabbits play in enabling pharma companies to stay engaged beyond prescriptions and contribute more meaningfully to patient outcomes?

Care delivery platforms like MedRabbits play a pivotal role in extending pharma’s presence into the patient’s everyday care journey. By integrating services such as home healthcare, remote monitoring, and coordinated clinical pathways, these platforms create continuous touchpoints that go far beyond the prescription stage.

For pharma companies, this enables deeper engagement through adherence support, patient education, and ongoing monitoring of treatment progress. Additionally, such platforms facilitate the generation of real-world data, offering valuable insights into patient behavior, therapy effectiveness, and outcome trends. This not only enhances patient care but also allows pharma to align more closely with outcome-driven goals.

As healthcare shifts toward more connected and patient-centric ecosystems, how will integrated care providers influence the future of outcome-driven healthcare?

The success of integrated care providers will go a long way in determining the future development of value-driven healthcare. Through the integration of various healthcare services to form one patient-centric approach, there will always be coordination, timeliness, and personalization of care provided.

Through their integration, data will flow smoothly throughout the entire care continuum, thus becoming an important aspect that will aid in measuring results, optimizing, and tracking patient progress and outcome. In essence, the concept of care will become proactive rather than reactive in nature. In conclusion, integrated care providers will play an instrumental role in enabling the shift from traditional models of care to value-based care systems.

Also read: AI Is Becoming India’s New Healthcare Workforce: Meet Top 10 Indian HealthTech Companies of 2026

Looking ahead, what will define success for pharma companies in an outcome-driven model, and what role will ecosystem partnerships play in achieving it?

Outcome-oriented medicine would see pharmaceutical companies’ success measured on their ability to make an actual difference. Patient compliance, clinical outcomes, fewer hospital stays, and efficiency are some examples of metrics they would use to measure their success.

To do this, they must change their modus operandi from operating in silos to building collaborative ecosystems. They will need to work with integrated care networks, healthcare institutions, and technology partners to achieve holistic visibility and coordinate patient care.

The future for pharma is in moving away from being a company solely focused on products to one centered around patients and collaboration.

Views expressed by: Suhasini Deshmukh, Co founder and Director at MedRabbits Healthcare

Like

Dislike

Be a part of Elets Collaborative Initiatives. Join Us for Upcoming Events and explore business opportunities. Like us on Facebook , connect with us on LinkedIn and follow us on Twitter , Instagram.

"Exciting news! Elets technomedia is now on WhatsApp Channels Subscribe today by clicking the link and stay updated with the latest insights!" Click here!